Research finds benefits of early anticlotting therapy in moderate COVID-19
Larner College of Medicine at the University of Vermont COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly in the lungs, and is believed to contribute to progression to severe disease and death. New trial results show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. The study, led by...
Source: miragenews.com